Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 7—July 2012
Letter

Treatment Duration for Patients with Drug-Resistant Tuberculosis, United States

Carla A. WinstonComments to Author  and Kiren Mitruka
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure

Treatment duration, by drug-resistance pattern, among reported tuberculosis case-patients who completed treatment, United States, 2006. Cases were among patients who were alive and initiated therapy at diagnosis and who had start and end therapy dates as well as results for initial drug susceptibility testing to isoniazid, rifampin, and ethambutol. Susceptibility testing was conducted on culture-positive Mycobacterium tuberculosis isolates from any specimen type.

Figure. . . Treatment duration, by drug-resistance pattern, among reported tuberculosis case-patients who completed treatment, United States, 2006. Cases were among patients who were alive and initiated therapy at diagnosis and who had start and end therapy dates as well as results for initial drug susceptibility testing to isoniazid, rifampin, and ethambutol. Susceptibility testing was conducted on culture-positive Mycobacterium tuberculosis isolates from any specimen type.

Main Article

Page created: June 08, 2012
Page updated: June 08, 2012
Page reviewed: June 08, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external